Vis enkel innførsel

dc.contributor.authorGhotbi, Jacob
dc.contributor.authorSahakyan, Mushegh
dc.contributor.authorSøreide, Kjetil
dc.contributor.authorFretland, Åsmund Avdem
dc.contributor.authorRøsok, Bård Ingvald
dc.contributor.authorTholfsen, Tore
dc.contributor.authorWaage, Anne
dc.contributor.authorEdwin, Bjørn von Gohren
dc.contributor.authorLabori, Knut Jørgen
dc.contributor.authorYakub, Sheraz
dc.contributor.authorKleive, Dyre
dc.date.accessioned2023-04-24T09:06:28Z
dc.date.available2023-04-24T09:06:28Z
dc.date.created2023-03-28T14:16:11Z
dc.date.issued2022
dc.identifier.issn2366-1070
dc.identifier.urihttps://hdl.handle.net/11250/3064431
dc.description.abstractMinimally invasive pancreatoduodenectomy has gained popularity throughout the last decade. For laparoscopic pancreatoduodenectomy, some high-level evidence exists, but with conflicting results. There are currently no published randomized controlled trials comparing robotic and open pancreatoduodenectomy. Comparative long-term data for patients with pancreatic ductal adenocarcinoma is lacking to date. Based on the existing evidence, current observed benefits of minimally invasive pancreatoduodenectomy over open pancreatoduodenectomy seem scarce, but retrospective data indicate the safety of these procedures in selected patients. As familiarity with the robotic platform increases, studies have shown an expansion in indications, also including patients with vascular involvement and even indicating favorable results in patients with obesity and high-risk morphometric features. Several ongoing randomized controlled trials aim to investigate potential differences in short- and long-term outcomes between minimally invasive and open pancreatoduodenectomy. Their results are much awaited.en_US
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleMinimally Invasive Pancreatoduodenectomy: Contemporary Practice, Evidence, and Knowledge Gapsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1007/s40487-022-00203-6
dc.identifier.cristin2137626
dc.source.journalOncology and Therapyen_US
dc.source.pagenumber301-315en_US
dc.identifier.citationOncology and Therapy. 2022, 10, 301-315.en_US
dc.source.volume10en_US
dc.source.issue2en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal